Document Type
Article
Publication Date
12-27-2021
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help fight against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bamlanivimab is a SARS-CoV-2 monoclonal antibody that is administered as an intravenous infusion to ambulatory patients with mild or moderate COVID-19, but a concern that arose was deciding the optimal location for patients to receive the medication. This report describes the development and implementation of a bamlanivimab infusion center in the emergency department of three hospitals in Orange County, California, shortly after bamlanivimab received emergency use authorization. As a result, a total of 601 patients received bamlanivimab in one of these three emergency departments between December 2020 to April 2021. The emergency department was shown to be an optimal setting for administration of bamlanivimab due to its convenience, accessibility, and capabilities for monitoring patients.
Recommended Citation
Pham DH, Wong S, Nguyen CT, Lee SC, Won KJ. Development of a bamlanivimab infusion process in the emergency department for outpatient COVID-19 patients. Healthcare. 2022;10(1):42. https://doi.org/10.3390/healthcare10010042
Copyright
The authors
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Included in
Epidemiology Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Pharmaceutics and Drug Design Commons, Virus Diseases Commons
Comments
This article was originally published in Healthcare, volume 10, issue 1, in 2022. https://doi.org/10.3390/healthcare10010042
This scholarship is part of the Chapman University COVID-19 Archives.